Could Ozempic, Wegovy, Mounjaro or Zepbound affect the optic nerve?
In this special episode of The Eye-Q Podcast™, neuro-ophthalmologist Dr. Rani Banik examines the rapidly evolving evidence surrounding GLP-1–based medications and nonarteritic anterior ischemic optic neuropathy, or NAION.
You’ll learn what NAION is, which patients may already be more susceptible, why optic disc anatomy and optic disc drusen matter, how diabetes and obstructive sleep apnea complicate the risk-benefit discussion, and what the major studies actually tell us.
Dr. Banik also discusses proposed mechanisms, a real-world patient experience with bilateral sequential NAION, practical guidance for patients and physicians, and the recent litigation surrounding these medications.
The key message: association is not the same as causation, and relative risk is not the same as absolute risk.
Do not discontinue a prescribed GLP-1 medication without discussing the risks and benefits with your treating clinician.
If this episode was helpful, follow The Eye-Q Podcast™, leave a rating or review, and share it with someone who takes—or prescribes—these medications.
Podden och tillhörande omslagsbild på den här sidan tillhör
Dr. Rani Banik. Innehållet i podden är skapat av Dr. Rani Banik och inte av,
eller tillsammans med, Poddtoppen.
